e-chondroprotection.com

News

Spanish researchers identify 16 proteins related to the response to osteoarthritis treatment

  • These proteins are potential biomarkers that could be used to predict the best treatment for each patient
  • They analyzed the differences in protein modulation between patients responding to celecoxib or to the combination of chondroitin sulfate and hydrochlorure of glucosamine, and patients not responding to these treatments.
  • The results of this study have been presented at the Osteoarthritis World Congress (OARSI) and have been accepted as scientific communication accepted for presentation at the European Congress of Rheumatology (EULAR).

Thirty percent of women with osteoarthritis experience anxiety and twenty percent experience depression, compared to twelve percent for men

  • Women suffering from osteoarthritis also have a 70% higher rate of hypertension and a 114% higher rate of peripheral vascular disease than women not suffering from osteoarthritis.
  • Specialists point out the importance of taking into account these specific factors in women before deciding the best therapeutic approach for osteoarthritis.
  • This data comes from the EMARTRO study which was presented for the first time at the 16th National Meeting in Women’s medicine and healthcare.

MOSAIC study, sponsored by Bioiberica, has been presented at ACR Annual Meeting: chondroitin sulfate is more efficient than anti-inflammatory drugs for delaying the progression of knee osteoarthritis

  • This is the main conclusion of a new clinical essay that proved, by means of Quantitative Magnetic Resonance, that pharmaceutical grade chondroitin sulfate is superior to an anti-inflammatory drug (celecoxib) for delaying the disease’s progression
  • The results also revealed that chondroitin sulfate possesses the same level of efficiency as celecoxib for the improvement of pain and mobility in knee osteoarthritis, with the added advantage of a higher safety profile
  • This research project has been selected by the American Academy of Rheumatology as one of the keynote addresses of this year’s annual meeting

Bioiberica enters the Australian market with its chondroitin sulfate thanks to its collaboration with BioCeuticals

BioCeuticals is the leading Australian practitioner-only therapeutic supplement company

“Osteoarthritis still remains an under diagnosed and under treated disease at all levels of healthcare”

This chronic inflammatory disease affects seven million Spaniards and causes 35 per cent of all visits to primary care centers

Family physicians play a key role in the early detection and treatment of the disease-family physicians are the healthcare professionals who can follow closely the evolution of their patients’ disease

A panel of osteoarthritis experts attending the 34th SEMERGEN national congress held in Malaga praised the efficacy and security of chondroprotection drugs and recommended them as the treatment of choice for osteoarthritis.

The chondroprotection blog, awarded with the “Web Médica Acreditada” and the “Web de interés Sanitario” seals of quality



These certifications are awarded by the Association of Physicians of Barcelona and by the portalesmedicos.com website, respectively.

Both organization’s committees have praised the accuracy, scientific interest and quality of Bioiberica’s Blog devoted to osteoarthritis.

The chondroprotection blog has had more than 5,500 visits from 3,000 unique users within less than six months.

More than 450 knee osteoarthritis patients are participating in a clinical trial that intend to confirm the efficacy of the combination of chondroitin sulphate and glycosamine.

It is a phase IV clinical trial currently being carried out in 38 medical centers in Spain, Germany, France and Poland.
The objective of the MOVES (Multicenter Osteoarthritis InterVEntion trial with Sysadoas) it is to prove that combining chondroitin sulfate and glucosamine sulfate is as efficient as celecoxib for the treatment of moderate to severe pain in knee osteoarthritis.
The study was presented at the 6th European Congress of Pharmacology that it is being held in Granada.

A new research paper proves that chondroitin sulphate inhibits angiogenesis, a mechanism of action involved in the rapid progression of osteoarthritis

The uncontrolled formation of new blood vessels in the synovial membrane (angiogenesis) may increase joint inflammation.

Inflammation is associated to loss of cartilage tissue and pain, which causes rapid progression of the disease.